Cargando…

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT

Detalles Bibliográficos
Autores principales:	chen, M., zhao, W., fu, M., Wang, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429187/ http://dx.doi.org/10.1097/01.HS9.0000849940.14968.56

Ejemplares similares

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
por: Yuehui, Lin
Publicado: (2023)

PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)
por: Kim, Juhyung, et al.
Publicado: (2023)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

PB1710: AN EXTENDED FLOW CYTOMETRY PANEL AS A SCREENING TOOL FOR PH-LIKE ALL
por: Cieloch, Adrianna, et al.
Publicado: (2023)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB1752: SAMATYA-PREDICTING SCORE IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): COMBINING CLINICAL FEATURES WITH FLOW CYTOMETRY
por: Cinli, Tahir Alper, et al.
Publicado: (2023)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
por: O Marani, L., et al.
Publicado: (2022)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
por: Gaspo, Rania, et al.
Publicado: (2023)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Wu, Jinghua, et al.
Publicado: (2023)

PB2137: INFLUENCE OF PREVIOUS RADIOTHERAPY ON THE EFFECT OF CART CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA
por: Shaomei, F.
Publicado: (2022)

PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA
por: Guo, Yuelu, et al.
Publicado: (2023)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

PB1806: ULTRA-SENSITIVE MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR LEUKEMIA PATIENTS USING SUPERRCA MUTATION ASSAYS WITH FLOW CYTOMETER READOUT
por: Chen, Lei, et al.
Publicado: (2023)

PB2434: DONOR CELL INDUCING IMMUNE-TOLERANCE IMPROVED ENGRAFTMENT IN TΑΒ+ CELL DEPLETED HSCT IN PATIENTS WITH THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
por: Xu, Qianwen, et al.
Publicado: (2023)

PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE
por: Antipova, A., et al.
Publicado: (2022)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

PB2260: CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE
por: Cacace, F., et al.
Publicado: (2022)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2020)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

PB2462: IMPACT OF ENGRAFTMENT SYNDROME ON THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC/HAPLOIDENTICAL PERIPHERAL BLOOD HSCT IN A SINGLE CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

PB2465: ALLOGENEIC HSCT OUTCOMES IN SIX PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER TREATED WITH CHEMOTERAPY AND PARP INHIBITORS
por: Maria Edoardo Maraglino, Alessio, et al.
Publicado: (2023)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt’s lymphoma: a case report
por: Cheng, Ling, et al.
Publicado: (2022)

Abnormalities by Multicolor Flow Cytometry for Detection of Minimal Residual Disease in Recipients of Allo-HSCT Originating from Donors: A Cohort Study
por: Wang, Hui, et al.
Publicado: (2023)

PB2680: THE ACTOR-PARTNER INTERDEPENDENCE MEDIATION EFFECT OF INTIMATE RELATIONSHIP ON DYADIC COPING AND FEAR OF CANCER RECURRENCE IN PATIENTS AND THEIR SPOUSES WITH HEMATOLOGICAL MALIGNANCY AFTER HSCT
por: Zhang, Qiuhui, et al.
Publicado: (2023)

PB1919: MATURE B-CELL NEOPLASMS CD5 NEGATIVE: CONFRONTATION CYTOMETRY-CYTOLOGY
por: Cheikh, Hanen Ben, et al.
Publicado: (2023)

Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2021)

PB1741: DIFFERENTIAL DIAGNOSIS OF T-LYMPHOBLASTIC LYMPHOMA/LEUKEMIA AND THYMOMA USING FLOW CYTOMETRY IN PLEURAL FLUID
por: Bae, Goeun, et al.
Publicado: (2023)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_srp0koj6i9nglhqlkrsuapesgh